Group 1 - The biopharmaceutical sector experienced significant upward movement, with companies such as Sanofi and Junshi Biosciences seeing notable gains [1] - Companies like Baotai, Sinovac Biotech, Changchun High-tech, and Ganli Pharmaceutical also followed suit with increases in their stock prices [1] - The influx of "smart money" into the market indicates a strategic shift in investment patterns, revealing insights into major players' trading behaviors [1]

智通财经5月27日电，三生国健涨超10%，科兴制药、振东制药、海翔药业、百奥泰、富祥药业、昊帆 生物涨超5%，舒泰神、金凯生科、凯莱英等跟涨。消息面上，中信证券研报称，2025年美国临床肿瘤 学会(ASCO)大会摘要数据于5月22日正式公布，多家国内创新药企业展示了优异的临床数据，标志着中 国药企正快速走向创新研发的国际前列。 创新药、CRO概念股再度走强 三生国健涨超10% ...

Core Viewpoint - The pharmaceutical sector in A-shares has shown significant performance in 2025, with many stocks experiencing substantial price increases, despite a recent pullback in the market [1][2]. Group 1: Market Performance - As of May 26, the A-share market saw the Shanghai Composite Index drop by 0.05% to 3346.84 points, with the Shenzhen Component Index down 0.41% and the ChiNext Index down 0.8% [1]. - The biopharmaceutical sector has had a strong year, with five stocks rising over 100% and 35 stocks increasing by more than 50% since the beginning of 2025 [1][2]. Group 2: Individual Stock Performance - Notable performers include Yong'an Pharmaceutical, which has seen a price increase of 171.34%, and other companies like Yipin Pharmaceutical and Sanofi National Health, with increases of 169.87% and 138.47%, respectively [3][4]. - The Wind data indicates that the Wande Innovation Drug Index and the Pharmaceutical and Biological Index have risen by 11.21% and 3.17%, respectively, outperforming major indices like the Shanghai Composite and CSI 300 [2]. Group 3: Factors Driving Stock Prices - Yong'an Pharmaceutical's stock price surge is attributed to rising international prices of taurine and strong sales performance of its functional beverage brand "Yijianeng" on e-commerce platforms [5]. - The recent authorization deal between Sanofi Pharmaceutical and Pfizer for a breakthrough PD-1/VEGF bispecific antibody has also driven stock prices, with potential total transaction value exceeding $6 billion [9]. - The acceleration of innovative drug development and the increasing focus on AI in healthcare are contributing factors to the rising stock prices of several pharmaceutical companies [10]. Group 4: Future Outlook - Analysts are optimistic about the investment opportunities in innovative drugs for the second half of 2025, citing the international competitiveness of China's innovative drug development [12]. - The pharmaceutical industry is expected to benefit from ongoing innovation, demographic trends, and favorable policy environments, with a focus on innovative drugs and consumer recovery [12].

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 三生国健药业（上海）股份有限公司（以下简称"公司"）第五 届监事会第五次会议通知于 2025 年 5 月 20 日以电话、电子邮件、专 人送达等方式发出。会议于 2025 年 5 月 26 日以现场结合通讯方式召 开。会议由监事会主席曹虹女士主持，会议应到监事 3 名，实到监事 程序符合《中华人民共和国公司法》和《三生国健药业（上海）股份 有限公司章程》的有关规定。 二、监事会会议审议情况 证券代码：688336 证券简称：三生国健 公告编号：2025-026 三生国健药业（上海）股份有限公司 第五届监事会第五次会议决议公告 （www.sse.com.cn）和指定媒体的公司《关于将部分项目节余资金用 于暂时补充流动资金以及调整部分募投项目拟投入募集资金金额的 公告》（公告编号：2025-025）。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案需提交公司股东大会审议。 特此公告。 三生国健药业（上海）股份有限公司监事会 经与会监事认真审 ...

Group 1 - The company announced an increase in temporary proposals for the 2025 Second Extraordinary General Meeting of Shareholders, which is scheduled for June 5, 2025 [1][2] - The shareholder, Fujian Pharmaceutical Co., Ltd., holding 35.92% of the shares, submitted a written proposal to include a resolution regarding the use of surplus funds for temporary liquidity and adjustments to the investment amounts of certain fundraising projects [2][3] - The original agenda for the shareholders' meeting remains unchanged, and the meeting will take place at the company's conference room in Shanghai [2][3] Group 2 - The network voting system for the shareholders' meeting will be conducted through the Shanghai Stock Exchange's online voting system, with voting available on the same day as the meeting [2][3] - The equity registration date for the shareholders' meeting remains unchanged [3] - The company has provided details regarding the voting rights and types of shareholders eligible to vote on the proposals [6][7]

Core Viewpoint - Sangfor Health plans to temporarily use surplus funds from several projects to supplement working capital and adjust the investment amounts for certain fundraising projects [1][12]. Fundraising Basic Situation - The company was approved to publicly issue 61,621,142 shares at a price of RMB 28.18 per share, raising a total of approximately RMB 1.736 billion, with a net amount of about RMB 1.634 billion after deducting fees [2][3]. Adjustments to Fundraising Projects - The company intends to reduce the investment amount for the "Innovative Antibody Drug Industrialization and Digital Factory Construction Project" from RMB 400 million to RMB 320 million, a reduction of RMB 80 million [1][6]. - The investment for the "Self-immune and Ophthalmic Disease Antibody Drug New Drug R&D Project" will be increased from RMB 610 million to RMB 690 million [1][6]. Surplus Fund Usage Plan - As of April 30, 2025, surplus funds from completed projects will be used to temporarily supplement working capital, amounting to RMB 66.6282 million [4][10]. - The surplus funds will be transferred to the "Supplementary Working Capital Project" account, with a usage period not exceeding 12 months from the date of shareholder meeting approval [4][10]. Reasons for Adjustments - The adjustments are made to enhance the efficiency of fund usage and align with the company's strategic focus on self-immune diseases and inflammation, which have significant unmet clinical needs [6][10]. - The company has shifted focus from certain oncology projects to prioritize self-immune disease projects, reflecting changes in market conditions [4][10]. Board and Supervisory Committee Approval - The board of directors and the supervisory committee have both approved the proposal to use surplus funds for working capital and adjust project investments, emphasizing that these actions will not harm the interests of shareholders [11][12].

华泰联合证券有限责任公司 关于三生国健药业（上海）股份有限公司 将部分项目节余资金用于暂时补充流动资金以及 调整部分募投项目拟投入募集资金金额的专项核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 三生国健药业（上海）股份有限公司（以下简称"三生国健"、"公司"或"发行人"） 首次公开发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管 理办法》、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022年修订）》、《上海证券交易所科创板股票上市规则（2025年 4月修订）》 及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》等法律法规的规定，对三生国健将部分项目节余资金用于暂时补充流 动资金以及调整部分募投项目拟投入募集资金金额进行了审慎核查，核查情况及 核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2020 年 6 月 23 日出具的《关于同意三生国 健药业（上海）股份有限公司首次公开发行股票注册的批复》（证监许可 [2020]1217 号），公司获准向社会公开发行人民币普通 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-025 三生国健药业（上海）股份有限公司 关于将部分项目节余资金用于暂时补充流动资金以 及调整部分募投项目拟投入募集资金金额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●三生国健药业（上海）股份有限公司（以下简称"公司"或"三 生国健"）拟将"抗体药物生产新建项目"、"抗肿瘤抗体药物的新 药研发项目"、"研发中心建设项目"及"补充营运资金项目"节余 资金 6,662.82 万元暂时补充流动资金。 ●拟缩减"创新抗体药物产业化及数字化工厂建设项目"募集 资金承诺投资总额，由 40,000.00 万元调减为 32,000.00 万元，调减 金额为 8,000.00 万元；拟增加"自身免疫及眼科疾病抗体药物的新 药研发项目"募集资金承诺投资总额，由 61,000.00 万元调增为 69,000.00 万元，调增金额为 8,000.00 万元。 ●公司于 2025 年 5 月 26 日召开第五届董事会第八次会议和第五 届监事会第五次会议，审 ...

| 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | A 股 | 688336 | 三生国健 | 2025/5/28 | 二、 增加临时提案的情况说明 2. 股东大会召开日期：2025 年 6 月 5 日 3. 股东大会股权登记日： 证券代码：688336 证券简称：三生国健 公告编号：2025-027 三生国健药业（上海）股份有限公司 关于2025年第二次临时股东大会增加临时提案的公 告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东大会有关情况 1. 股东大会的类型和届次： 2025年第二次临时股东大会 1. 提案人：富健药业有限公司 2. 提案程序说明 公司已于2025 年 5 月 21 日公告了股东大会召开通知，单独或者 合计持有35.92%股份的股东富健药业有限公司，在2025 年 5 月 26 日 提出临时提案并书面提交股东大会召集人。股东大会召集人按照《上 海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》有关 规定，现予以公 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-026 三生国健药业（上海）股份有限公司 第五届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 三生国健药业（上海）股份有限公司（以下简称"公司"）第五 届监事会第五次会议通知于 2025 年 5 月 20 日以电话、电子邮件、专 人送达等方式发出。会议于 2025 年 5 月 26 日以现场结合通讯方式召 开。会议由监事会主席曹虹女士主持，会议应到监事 3 名，实到监事 3 名。本次会议的召集与召开程序、出席会议人员资格及议事和表决 程序符合《中华人民共和国公司法》和《三生国健药业（上海）股份 有限公司章程》的有关规定。 二、监事会会议审议情况 经与会监事认真审议，并以投票表决的方式审议通过了如下决 议： 2025 年 5 月 27 日 2 （一）审议通过《关于将部分项目节余资金用于暂时补充流动资 金以及调整部分募投项目拟投入募集资金金额的议案》 1 具 体 内 容 详 见 公 司 同 日 刊 载 于 上 ...